Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis

Hepatology

Volumn 48, Issue 3, 2008, Pages 853-862

  Ohishi, Yuki ^a   Nakamura, Minoru ^a,b,c   Iio, Naomi ^a   Higa, Shingo ^a   Inayoshi, Mao ^a   Aiba, Yoshihiro ^b   Komori, Atsumasa ^a,b   Omagari, Katsuhisa ^d   Ishibashi, Hiromi ^a,b   Tsukamoto, Kazuhiro ^a,e  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d UNIVERSITY OF NAGASAKI   (Japan)

^e AVSS CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 3; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA SEQUENCE; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; JAPANESE; JAUNDICE; LIVER TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; JAPAN; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 51349140102     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22382     Document Type: Article

References (44)

1. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996;335:1570-1580.
2. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261-1273.
3. Prince M, Chetwynd A, Newman W, Metcalf JV, James OFW. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years. Gastroenterology 2002;123:1044-1051.
4. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OFW. Asymptomatic primary biliary cirrhosis: Clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004;53:865-870.
5. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. HEPATOLOGY 2007;45:118-127.
6. Gershwin ME, Ansari AA, Mackay IR, Nakamura Y, Nishio A, Rowley MJ, et al. Primary biliary cirrhosis: An orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210-225.
7. Itoh S, Ichida T, Yoshida T, Hayakawa A, Uchida M, Tashiro-Itoh T, et al. Autoantibodies against a 210 kDa. glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998;13:257-265.
8. Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001;34:366-372.
9. Nakamura M, Shimizu-Yoshida Y, Takii Y, Komori A, Yokoyama T, Ueki T, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for minitoring primary biliary cirrhosis. J Hepatol 2005;42:386-392.
10. Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of initial autoandbody profile and clinical outcome in primary biliary cirrhosis. HEPATOLOGY 2006;43:1135-1144.
11. Worman HJ, Courvalin J-C. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev 2003;2:211-217.
12. Selmi C, Invernizzi P, Zuin M, Podda M, Seldin MF, Gershwin ME. Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun 2005;6:543-556.
13. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment. Gastroenterology 2004;127:485-492.
14. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-37.
15. Brind AM, Bray GP, Portmann BC, Williams R. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut 1995;36:615-617.
16. Tsuji K, Watanabe Y, van de Water J, Nakanishi T, Kajiyama G, Parikh-Patel A, et al. Familial primary biliary cirrhosis in Hiroshima. J Autoimmun 1999;13:171-178.
17. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: association with disease progression and disease susceptibility. Gut 2001;48:397-402.
18. Selmi C, Invernizzi P, Tripputi P, Battezzati PM, Bignotto M, Zuin M, et al. T-cell receptor polymorphism in primary biliary cirrhosis. Ann Ital Med Int 2003;18:149-153.
19. Selmi C, Zuin M, Biondi ML, Invernizzi P, Battezzati PM, Bernini M, et al. Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: Association with disease severity. J Gastroenterol Hepatol 2003;18:1150-1155.
20. Kimura Y, Selmi C, Leung PSC, Mao TK, Schauer J, Watnik M, et al. Genetic polymorphisms; influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. HEPATOLOGY 2005;41:55-63.
21. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002; 123:1649-1659.
22. Noé J, Stieger B, Meier PJ. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 2002;123:1659-1666.
23. van der Bliek AM, Kooiman PM, Schneider C, Borst P. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 1988;71:401-411.
24. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, et al. MDR1 P-glycoprotein is a lipid translocase if broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996;87:507-517.
25. Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004;14:91-102.
26. Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. HEPATOLOGY 2004;39:779-791.
27. Poupen RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-890.
28. Poupon RE, Lindor KD, Parés A, Chazouilléres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39: 12-16.
29. Leuschner M, Dietrich CF, You T, Seidl C, Raedle J, Herrmann G, et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000;46:121-126.
30. Corpechot C, Carrar F, Bonnand A-M, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. HEPATOLOGY 2000;32:1196-1199.
31. Plass JRM, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PLM, et al. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. HEPATOLOGY 2002;35:589-596.
32. Huang L, Zhao A, Lew J-L, Zhang T, Hrywna Y, Thompson JR, et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 2003;278:51085-51090.
33. Marschall H-U, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in human. Gastroenterology 2005;129:476-485.
34. Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med 1967;60:1257-1260.
35. Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodexoycholic acid treatment on histology progression. HEPATOLOGY 1999; 29:1007-1012.
36. Song CM, Yeo BH, Tantoso E, Yang Y, Lim YP, Li K-B, et al. iHAP-integrated haplotype analysis pipeline for characterizing the haplotype structure of genes. BMC Bioinformatics 2006;7:525.
37. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, van Deemter L, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-462.
38. Oude Elferink RPJ, Ottenhoff R, van Wijland M, Smit JJM, Schinkel AH, Groen AK. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest 1995;95:31-38.
39. Ali S, Zakim D. The effects of bilirubin on the thermal properties of phosphatidylcholine bilayers. Biophys J 1993;65:101-105.
40. Oude Elferink RPJ, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Eur J Physiol 2007;453: 601-610.
41. de Vree JML, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998;95:282-287.
42. Jacquemin E, de Vree JML, Cresteil D, Sokal EM, Sturm E, Dumont M, et al. The wide spectrum of multidrug resistance 3 deficiency: From neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001;120: 1448-1458.
43. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999;353:210-211.
44. Lucena JF, Herrero JI, Quiroga J, Sangro B, Garcia-Foncillas J, Zabalegui N, et al. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 2003;124:1037-1042.